Nurix Q2 2023 Earnings Report
Key Takeaways
Nurix Therapeutics reported revenue of $30.7 million for the quarter ended May 31, 2023, which included a $20 million licensing payment from Gilead. The net loss was $24.3 million, or ($0.45) per share. Cash, cash equivalents and marketable securities totaled $308.6 million as of May 31, 2023.
Announced Phase 1b expansion cohorts for NX-2127 in non-Hodgkin’s lymphomas
Presented data highlighting the potent cellular activity of both NX-5948 and NX-2127 against BTKi resistance mutations
Received $20 million licensing payment from Gilead for NX-0479, an oral IRAK4 degrader for the treatment of rheumatoid arthritis and inflammatory diseases
Maintained strong financial position with cash and marketable securities of $308.6 million as of May 31, 2023
Nurix
Nurix
Nurix Revenue by Segment
Forward Guidance
In the second half of 2023, Nurix expects to generate clinical data that will provide additional insight into the potential specific applications of both the NX-5948 and NX-2127 BTK degrader programs while they continue to advance their internal and partnered programs.